Close Menu

NEW YORK – California-based drug company Aadi Bioscience and EOC Pharma, a firm based in China specializing in cancer therapies, have signed an exclusive licensing deal to develop and commercialize Aadi's mTOR inhibitor ABI-009 in Greater China.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.